Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9

Kohei Yamamoto, Marina Mukai, Kenjiro Nagaoka, Keiko Hayashi, Hiroyuki Hichiya, Kenji Okada, Mikio Murata, Masato Shigeyama, Shizuo Narimatsu, Nobumitsu Hanioka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

UDP-glucuronosyltransferase 1A9 (UGT1A9) contributes to the glucuronidation of numerous drugs. Cynomolgus monkeys are regarded as experimental animals similar to humans in studies on safety evaluation and biotransformation for drug development. In this study, the similarities and differences in the enzymatic properties of UGT1A9 between humans and cynomolgus monkeys were precisely identified. UGT1A9 cDNAs of humans (humUGT1A9) and cynomolgus monkeys (monUGT1A9) were cloned, and the corresponding proteins were heterologously expressed in Sf9 cells. The enzymatic properties of UGT1A9s were characterized by kinetic analysis of propofol glucuronidation. The amino acid homology between humUGT1A9 and monUGT1A9 was 93.2 %. Propofol glucuronidation by recombinant humUGT1A9 and monUGT1A9 exhibited substrate inhibition and monophasic Michaelis-Menten kinetics, respectively. The Km, Vmax and CLint values of humUGT1A9 were 15.0 μM, 1.56 nmon/min/mg protein and 107 μL/min/mg protein, respectively. The Km value of monUGT1A9 was 8.8-fold higher than humUGT1A9, and the Vmax and CLint values of monUGT1A9 were 15 and 2 % of humUGT1A9, respectively. These findings suggest that the enzymatic properties of UGT1A9 are considerably different between humans and cynomolgus monkeys, although humUGT1A9 and monUGT1A9 were highly conserved at the amino acid level. The information on species differences in UGT1A9 function gained in this study should help with the in vivo extrapolation of drug metabolism.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
DOIs
Publication statusAccepted/In press - 2014

Fingerprint

Macaca fascicularis
Propofol
Sf9 Cells
Amino Acids
Drug Evaluation
Proteins
Biotransformation
Pharmaceutical Preparations
Complementary DNA
UDP-glucuronosyltransferase 1A9
Safety

Keywords

  • Cynomolgus monkey
  • Propofol
  • UDP-glucuronosyltransferase (UGT)
  • UGT1A9

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. / Yamamoto, Kohei; Mukai, Marina; Nagaoka, Kenjiro; Hayashi, Keiko; Hichiya, Hiroyuki; Okada, Kenji; Murata, Mikio; Shigeyama, Masato; Narimatsu, Shizuo; Hanioka, Nobumitsu.

In: European Journal of Drug Metabolism and Pharmacokinetics, 2014, p. 1-8.

Research output: Contribution to journalArticle

Yamamoto, K, Mukai, M, Nagaoka, K, Hayashi, K, Hichiya, H, Okada, K, Murata, M, Shigeyama, M, Narimatsu, S & Hanioka, N 2014, 'Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9', European Journal of Drug Metabolism and Pharmacokinetics, pp. 1-8. https://doi.org/10.1007/s13318-014-0177-x
Yamamoto, Kohei ; Mukai, Marina ; Nagaoka, Kenjiro ; Hayashi, Keiko ; Hichiya, Hiroyuki ; Okada, Kenji ; Murata, Mikio ; Shigeyama, Masato ; Narimatsu, Shizuo ; Hanioka, Nobumitsu. / Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. In: European Journal of Drug Metabolism and Pharmacokinetics. 2014 ; pp. 1-8.
@article{a5c6b0af58384e89a29d1daeec800e37,
title = "Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9",
abstract = "UDP-glucuronosyltransferase 1A9 (UGT1A9) contributes to the glucuronidation of numerous drugs. Cynomolgus monkeys are regarded as experimental animals similar to humans in studies on safety evaluation and biotransformation for drug development. In this study, the similarities and differences in the enzymatic properties of UGT1A9 between humans and cynomolgus monkeys were precisely identified. UGT1A9 cDNAs of humans (humUGT1A9) and cynomolgus monkeys (monUGT1A9) were cloned, and the corresponding proteins were heterologously expressed in Sf9 cells. The enzymatic properties of UGT1A9s were characterized by kinetic analysis of propofol glucuronidation. The amino acid homology between humUGT1A9 and monUGT1A9 was 93.2 {\%}. Propofol glucuronidation by recombinant humUGT1A9 and monUGT1A9 exhibited substrate inhibition and monophasic Michaelis-Menten kinetics, respectively. The Km, Vmax and CLint values of humUGT1A9 were 15.0 μM, 1.56 nmon/min/mg protein and 107 μL/min/mg protein, respectively. The Km value of monUGT1A9 was 8.8-fold higher than humUGT1A9, and the Vmax and CLint values of monUGT1A9 were 15 and 2 {\%} of humUGT1A9, respectively. These findings suggest that the enzymatic properties of UGT1A9 are considerably different between humans and cynomolgus monkeys, although humUGT1A9 and monUGT1A9 were highly conserved at the amino acid level. The information on species differences in UGT1A9 function gained in this study should help with the in vivo extrapolation of drug metabolism.",
keywords = "Cynomolgus monkey, Propofol, UDP-glucuronosyltransferase (UGT), UGT1A9",
author = "Kohei Yamamoto and Marina Mukai and Kenjiro Nagaoka and Keiko Hayashi and Hiroyuki Hichiya and Kenji Okada and Mikio Murata and Masato Shigeyama and Shizuo Narimatsu and Nobumitsu Hanioka",
year = "2014",
doi = "10.1007/s13318-014-0177-x",
language = "English",
pages = "1--8",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",

}

TY - JOUR

T1 - Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9

AU - Yamamoto, Kohei

AU - Mukai, Marina

AU - Nagaoka, Kenjiro

AU - Hayashi, Keiko

AU - Hichiya, Hiroyuki

AU - Okada, Kenji

AU - Murata, Mikio

AU - Shigeyama, Masato

AU - Narimatsu, Shizuo

AU - Hanioka, Nobumitsu

PY - 2014

Y1 - 2014

N2 - UDP-glucuronosyltransferase 1A9 (UGT1A9) contributes to the glucuronidation of numerous drugs. Cynomolgus monkeys are regarded as experimental animals similar to humans in studies on safety evaluation and biotransformation for drug development. In this study, the similarities and differences in the enzymatic properties of UGT1A9 between humans and cynomolgus monkeys were precisely identified. UGT1A9 cDNAs of humans (humUGT1A9) and cynomolgus monkeys (monUGT1A9) were cloned, and the corresponding proteins were heterologously expressed in Sf9 cells. The enzymatic properties of UGT1A9s were characterized by kinetic analysis of propofol glucuronidation. The amino acid homology between humUGT1A9 and monUGT1A9 was 93.2 %. Propofol glucuronidation by recombinant humUGT1A9 and monUGT1A9 exhibited substrate inhibition and monophasic Michaelis-Menten kinetics, respectively. The Km, Vmax and CLint values of humUGT1A9 were 15.0 μM, 1.56 nmon/min/mg protein and 107 μL/min/mg protein, respectively. The Km value of monUGT1A9 was 8.8-fold higher than humUGT1A9, and the Vmax and CLint values of monUGT1A9 were 15 and 2 % of humUGT1A9, respectively. These findings suggest that the enzymatic properties of UGT1A9 are considerably different between humans and cynomolgus monkeys, although humUGT1A9 and monUGT1A9 were highly conserved at the amino acid level. The information on species differences in UGT1A9 function gained in this study should help with the in vivo extrapolation of drug metabolism.

AB - UDP-glucuronosyltransferase 1A9 (UGT1A9) contributes to the glucuronidation of numerous drugs. Cynomolgus monkeys are regarded as experimental animals similar to humans in studies on safety evaluation and biotransformation for drug development. In this study, the similarities and differences in the enzymatic properties of UGT1A9 between humans and cynomolgus monkeys were precisely identified. UGT1A9 cDNAs of humans (humUGT1A9) and cynomolgus monkeys (monUGT1A9) were cloned, and the corresponding proteins were heterologously expressed in Sf9 cells. The enzymatic properties of UGT1A9s were characterized by kinetic analysis of propofol glucuronidation. The amino acid homology between humUGT1A9 and monUGT1A9 was 93.2 %. Propofol glucuronidation by recombinant humUGT1A9 and monUGT1A9 exhibited substrate inhibition and monophasic Michaelis-Menten kinetics, respectively. The Km, Vmax and CLint values of humUGT1A9 were 15.0 μM, 1.56 nmon/min/mg protein and 107 μL/min/mg protein, respectively. The Km value of monUGT1A9 was 8.8-fold higher than humUGT1A9, and the Vmax and CLint values of monUGT1A9 were 15 and 2 % of humUGT1A9, respectively. These findings suggest that the enzymatic properties of UGT1A9 are considerably different between humans and cynomolgus monkeys, although humUGT1A9 and monUGT1A9 were highly conserved at the amino acid level. The information on species differences in UGT1A9 function gained in this study should help with the in vivo extrapolation of drug metabolism.

KW - Cynomolgus monkey

KW - Propofol

KW - UDP-glucuronosyltransferase (UGT)

KW - UGT1A9

UR - http://www.scopus.com/inward/record.url?scp=84892695536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892695536&partnerID=8YFLogxK

U2 - 10.1007/s13318-014-0177-x

DO - 10.1007/s13318-014-0177-x

M3 - Article

C2 - 24470170

AN - SCOPUS:84892695536

SP - 1

EP - 8

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

ER -